Oncternal Therapeutics Inc (ONCT)

[kmx_swing]

Two many insiders were buying prior to appointment of Dr. Garry Neil. As stated, he has got a proven track record of turning new science into breakthrough commercial products. And in last conference call report from seeking alpha they stated :
1) enobosarm - we expect to have the results of Stage 1, which is the first 18 invaluable patients per each dose by yearend...We expect this data to be published later this year.
2) SARD - our compounds degrade the full length and variant forms of the androgen receptor. We hope to have several IND-ready compounds that could be taken into the clinic in 2017.
3) SUI - There are no orally available effective treatment options for SUI. We expect to have results from this trial in the second half of this year.
Addditonly they said...: we're optimistic that our ongoing efforts will allow us to achieve key data milestones across several programs in 2016.
It seems the time is starting to come. Why would they have appointed somebody, who helps to market the drugs, if they feel they have no drug to market?